65 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
28 Jun 21
Other Events
6:07am
Article 5(3) received on 5/21/2021. © 2021 Vir Biotechnology, Inc. U.S., EU†
Chronic HBV: Our Approach to Functional Cure We believe that chronic HBV … (CHB) is a viral disease resulting in immune dysfunction We believe that chronic HBV infection results in immune dysfunction via the expression
8-K
EX-99.1
VIR
Vir Biotechnology Inc
28 Jan 21
Other Events
4:05pm
Exhibit 99.1
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid … : VIR) today announced initial topline data from its ongoing trial of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. Data from
8-K
EX-99.1
VIR
Vir Biotechnology Inc
4 Nov 21
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
4:07pm
efforts to develop a functional cure for chronic hepatitis B. Additionally, our strong cash position allows us both the flexibility … for VIR-7832.
Chronic Hepatitis B Virus (HBV)
In July, the Company initiated the Phase 2 MARCH trial to evaluate the combination of VIR-2218 and VIR
8-K
EX-99.1
VIR
Vir Biotechnology Inc
6 May 21
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:24pm
million doses to patients in the first year following potential EUA, and several fold that in the second year, depending on titer and yield.
Chronic … , in both treatment-experienced and treatment-naïve patients with HBV. The trial, which is aimed at developing a functional cure for chronic HBV
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials –
– Company expanding strategic focus to autoimmune diseases and immuno … on our multiple clinical stage programs and look forward to sharing Phase 2 data from our chronic hepatitis B MARCH Part B and chronic hepatitis delta
8-K
EX-99.1
g4vb33d4exe47xqn3e
5 Aug 21
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
4:14pm
8-K
EX-99.1
prgop
13 Apr 21
Other Events
4:06pm
8-K
EX-99.2
f9hles5sc uxp3715b
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.1
6qxej9a 7zsvagxr605s
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
qrj8r2kyemns ycue
28 Jun 21
Other Events
6:07am
8-K
EX-99.1
z1ewfz53
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
8-K
EX-99.2
hbef8i r4
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm
8-K
EX-99.1
o42hbvms1gs lbjvmca
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm
8-K
EX-99.1
8n3yxwt llhnjvuhp
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
EX-99.1
hrlgaoo22gp1jn61
3 Nov 22
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
70puejcnjzmwsp svz4i
9 Aug 22
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
r5i f0wf0aoovd2xtoca
25 Feb 21
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:15pm
8-K
jbbhp
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
UPLOAD
hce5evca
25 Jul 19
Letter from SEC
12:00am
8-K
EX-99.1
h157ahd3we l0leja0bn
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am